Proportion of flash CGM continuers who experienced a severe hypoglycemic event decreased by 86% ( P = 0.037) no change was seen in the SMBG group. No severe hypoglycemic events were reported.ġ2-month, prospective, observational study (Belgium)ģ35 children/adolescents (10.9–16.3 years of age) with type 1 diabetes Number of hypoglycemic events (<70 mg/dL) increased from 16.9 to 22.9 events per month ( P <0.05). Number of daily scans was negatively correlated with decreased A1C. The proportion of participants who reported hypoglycemia decreased from 93.5 to 91.0% ( P 7.5%. Severe hypoglycemic events decreased from 14.6 to 7.8% ( P 70 mmol/mol, the A1C decrease was −9 (95% CI −12 to 5) mmol/mol. Hospitalizations decreased from 3.3 to 2.2% ( P = 0.031). Hospitalization with DKA and/or severe hypoglycemia 5.8%, P <0.0001), a metric that is often not reported in RCTs and provides an informative indicator of economic benefit.ġ2-month, prospective, observational, multicenter, cohort study (Belgium) Moreover, fewer subjects were absent from work (2.9 vs. Although measures of general and diabetes-specific QoL were relatively high at baseline and remained stable throughout the study, treatment satisfaction was increased by study end. Over the 12-month study period, admissions for severe hypoglycemia and/or diabetic ketoacidosis (DKA) decreased from 3.3 to 2.2% ( P = 0.031), and fewer individuals reported severe hypoglycemic events (7.8 vs. For example, one prospective, observational study assessed the impact of flash CGM in an unselected real-world cohort of 1,913 adults with type 1 diabetes ( 23). While these studies confirm significant reductions in A1C ( 23– 25, 32) and hypoglycemia ( 23, 24) within large populations with type 1 or type 2 diabetes, they also provide strong evidence linking metabolic outcomes of flash CGM use to reductions in health care resource utilization. Glycemic and Economic Benefits of Flash CGM Use in Real-World StudiesĪs presented in Table 2, results from recently published prospective, observational studies closely align with glycemic benefits reported in earlier RCTs and also demonstrate the value of flash CGM use on cost outcomes and quality of life (QoL) measures ( 23– 31). Importantly, any level of hypoglycemia confers substantial indirect costs on employers as well as on individuals with diabetes because of increased work days lost ( 16– 18). Other studies have had similar findings ( 15). Significant indirect costs were incurred during the prospective period, with lost work time averaging 2.0 days for patients with type 1 diabetes and 1.8 days for those with type 2 diabetes. During the prospective period, 83% of patients with type 1 diabetes and 46.5% of those with type 2 diabetes reported hypoglycemia, resulting in increased blood glucose monitoring, a marked increase in contact with health care providers, and increased hospitalizations. The global HAT (Hypoglycemia Assessment Tool) study, a 6-month retrospective and 4-week prospective investigation of 27,585 insulin-treated patients (type 1 diabetes, n = 8,022 type 2 diabetes, n = 19,563) in 24 countries noted the costs of inadequate glycemic control ( 15).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |